A Phase 1b Clinical Trial Enabled by ddPCR

In this phase 1b trial, clinicians tested the use of azacitidine, a chemotherapy drug, in combination with small-molecule drug APR-246 in patients with myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML) with TP53 mutations. Download the abstract to discover how ddPCR was effective at defining patient-specific depth of remission.